ABCL
Price
$4.29
Change
+$0.02 (+0.47%)
Updated
Jan 14 closing price
Capitalization
1.29B
40 days until earnings call
Intraday BUY SELL Signals
CDXS
Price
$1.78
Change
+$0.07 (+4.09%)
Updated
Jan 14 closing price
Capitalization
160.78M
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs CDXS

Header iconABCL vs CDXS Comparison
Open Charts ABCL vs CDXSBanner chart's image
AbCellera Biologics
Price$4.29
Change+$0.02 (+0.47%)
Volume$4.1M
Capitalization1.29B
Codexis
Price$1.78
Change+$0.07 (+4.09%)
Volume$560.18K
Capitalization160.78M
ABCL vs CDXS Comparison Chart in %
View a ticker or compare two or three
VS
ABCL vs. CDXS commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and CDXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ABCL: $4.29 vs. CDXS: $1.78)
Brand notoriety: ABCL and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 99% vs. CDXS: 49%
Market capitalization -- ABCL: $1.29B vs. CDXS: $160.78M
ABCL [@Biotechnology] is valued at $1.29B. CDXS’s [@Biotechnology] market capitalization is $160.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABCL and CDXS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 4 TA indicator(s) are bullish while CDXS’s TA Score has 2 bullish TA indicator(s).

  • ABCL’s TA Score: 4 bullish, 5 bearish.
  • CDXS’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than CDXS.

Price Growth

ABCL (@Biotechnology) experienced а +3.87% price change this week, while CDXS (@Biotechnology) price change was +4.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 24, 2026.

CDXS is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.29B) has a higher market cap than CDXS($161M). ABCL YTD gains are higher at: 25.439 vs. CDXS (9.202). CDXS has higher annual earnings (EBITDA): -55.32M vs. ABCL (-212.36M). ABCL has more cash in the bank: 496M vs. CDXS (58.7M). CDXS has less debt than ABCL: CDXS (68.6M) vs ABCL (142M). CDXS has higher revenues than ABCL: CDXS (52.9M) vs ABCL (35.3M).
ABCLCDXSABCL / CDXS
Capitalization1.29B161M799%
EBITDA-212.36M-55.32M384%
Gain YTD25.4399.202276%
P/E RatioN/AN/A-
Revenue35.3M52.9M67%
Total Cash496M58.7M845%
Total Debt142M68.6M207%
FUNDAMENTALS RATINGS
CDXS: Fundamental Ratings
CDXS
OUTLOOK RATING
1..100
65
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLCDXS
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 15 days ago
85%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
CDXS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WALSX12.830.08
+0.63%
Wasatch Long/Short Alpha Investor
MNDIX36.460.17
+0.47%
MFS New Discovery I
FFIDX113.71N/A
N/A
Fidelity
GGEIX25.07-0.14
-0.56%
Nationwide Schroders Global Eq R6
HIMCX24.17-0.16
-0.66%
Hartford MidCap HLS IA

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+0.47%
RXRX - ABCL
58%
Loosely correlated
+3.41%
ABSI - ABCL
58%
Loosely correlated
+1.21%
CRSP - ABCL
56%
Loosely correlated
+1.26%
VCYT - ABCL
56%
Loosely correlated
-1.39%
DNA - ABCL
51%
Loosely correlated
+2.39%
More

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+4.09%
DNLI - CDXS
50%
Loosely correlated
+0.88%
NTLA - CDXS
50%
Loosely correlated
+2.39%
BEAM - CDXS
50%
Loosely correlated
+2.49%
ABCL - CDXS
50%
Loosely correlated
+0.47%
ABSI - CDXS
49%
Loosely correlated
+1.21%
More